A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Status:
Completed
Trial end date:
2021-04-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of risankizumab versus
placebo during induction therapy in participants with moderately to severely active Crohn's
disease (CD).